STUDY OF FORCED DEGRADATION BEHAVIOUR OF A NOVEL PROTEASOME-INHIBITING ANTICANCER DRUG BY LC-MS AND DEVELOPMENT OF A VALIDATED STABILITY-INDICATING ASSAY METHODAbstract
In the present study, comprehensive stress testing of Carfilzomib, a newly approved proteasome-inhibiting anticancer drug was carried out according to ICH guideline Q1A (R2). The drug was subjected to acid (0.1N HCl), neutral and alkaline (0.1N NaOH) hydrolytic conditions at 70 ºC, as well as to oxidative decomposition at room temperature. Photolysis was carried out in 0.1N HCl, water and 0.1N NaOH at 40 ºC. LC-PDA and LC-MS investigated the products formed under different stress conditions. The LC-PDA method that could separate all degradation products formed under various stress conditions involved a C18 column and a mobile phase comprising of ACN and phosphate buffer (pH 3). The flow rate and detection wavelengths were 1 ml/min and 220 nm, respectively. The developed method was found to be precise, accurate, specific and selective. It was suitably modiﬁed for LC-MS studies by replacing phosphate buffer with water, where pH was adjusted to 3.0 with formic acid. The drug showed instability in the solution state (under acidic, neutral, alkaline and oxidative stress conditions), but was relatively stable in the solid-state, except the formation of minor products under accelerated conditions. Primarily, maximum degradation products were formed in acid conditions, though the same were also produced variably under other stress conditions. LC-MS fragmentation studies characterized the products. Based on the results, a complete degradation pathway for the drug could be proposed. LC-ESI-MS/MS characterized the major stress degradation product, and its fragmentation pathway was proposed.
B. A. Agarwal * and S. V. Gandhi
Department of Pharmaceutical Chemistry, A.I.S.S.M.S College of Pharmacy, Pune, Maharashtra, India.
19 June 2018
12 September 2018
06 September 2018
01 March 2019